Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Non-government healthcare institution “Khabarovsk-1 Road clinical hospital, Open Society “Russian Railways” (Khabarovsk, Russia)
    2. State educational government-financed institution of higher professional education “Far East state medical university”, Ministry of Healthcare of the Russian Federation (Khabarovsk, Russia)

    Keywords:irritable bowel syndrome with or without diarrhea, small intestinal bacterial overgrowth, mebeverin, rifaximin, probiotics

    Abstract:Aim. To assess the effect of therapy with mebeverine, rifaximin and probiotics on clinical symptoms, small intestinal bacterial overgrowth (SIBO) eradication, fecal calprotectin (FC) level and the quality of life in irritable bowel syndrome patients with (IBS-D) or without diarrhea (IBS without D). Material and methods. Patients with IBS-D (n=74) or IBS without D (n=127) were randomly divided into 2 subgroups homogeneous for sex, age, FC level and IBS severity. Patients of subgroup I received mebeverine 0,4 g/day for 1 month in combination with sequential therapy, including rifaximin 0,8 g/day 6 days followed by S. boulardii 0,5 g/day 10 days, and followed by probiotic “Bifiform” 2 capsules/day for 15 days. Patients of subgroup II received mebeverine 0,4 g/day for 3 months in combination with 3 courses of sequential therapy, without interruption, including rifaximin and probiotics in the same doses. IBS severity (IBS-SS), quality of life (SF-36), FC level and frequency SIBO eradication were estimated prior to onset of treatment and after its termination. Results. Differences between the 2 subgroups of IBS-D patients in clinical improvement and SIBO eradication after 1 or 3 months of therapy weren’t significant (р>0,05). Reduction of clinical symptoms and SIBO eradication were significantly more frequent in IBS patients without D after 3 months than 1 month (p<0.012). A significant decrease in the patient’s proportion with elevated FC levels occurred after 3 months (p <0.0001). Conclusions. The three-month therapy is significantly better than the monthly therapy in IBS patients without D in reducing the IBS severity, increasing the SIBO eradication frequency and the patient’s proportion with normal FC. Differences in clinical efficacy after 1 or 3 months of therapy in IBS-D patients with normal FC levels aren’t detected (p>0.05). Normalization of FC level in IBS-D patients with elevated FC levels (>100 μg/g) is significantly more likely to be detected after 3 months of therapy than in one (p <0.0001).

      1. Maev I. V., Cheremushkin S. V., Kucheryavyi Yu.A. et al. Pharmacotherapy for irritable bowel syndrome in the context of evidence-based medicine. Ter Arkh. – 2015. – Vol. 87, N2. – P. 4–10. (in Russian).
      2. Ivashkin V. T., Shelygin Yu.A., Baranskaya Ye.K. et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. – 2017. – Vol. 27, N5. – P. 76–93. (in Russian).
      3. Lacy B. E., Mearin F., Chang L. et al. Bowel Disorders. Gastroenterology. – 2016. – Vol. 150, N6. – P. 1393–1407.
      4. Pimentel M., Lembo A., Chey W. D. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. – 2011. – Vol. 364. – P. 22–32.
      5. Rosania R., Giorgio F., Principi M. et al. Effect of probiotic or prebiotic supplementation on antibiotic therapy in the small intestinal bacterial overgrowth: a comparative evaluation. Curr Clin Pharmacol. – 2013. – Vol. 8, N2. – Р. 169–172.
      6. Boltin D., Perets T. T., Shporn E. et al. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome. Annals of Clinical Microbiology and Antimicrobials. – 2014. – Vol.13. – P. 49.
      7. Longstreth G. F., Thompson W. G., Chey W. D. et al. Functional bowel disorders. Gastroenterology. – 2006. – Vol. 130, N5. – Р. 1480–1491.
      8. Francis C. Y., Morris J., Whorwell P. J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. – 1997. – Vol. 11, N2. – P. 395–402
      9. Ghoshal U. C., Shukla R., Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut Liver. – 2017. – Vol. 11, N2. – P. 196–208.
      10. Andreyev D. N., Zaborovsky A. V., Trukhmanov A. S. Evaluation of the functional gastrointestinal diseases concept from standpoints of Rome IV (2016) diagnostic criteria (review) Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. – 2017. – Vol. 27, N1. – P. 4–11. (in Russian).
      11. Lee H. J., Choi J. K., Ryu H. S. et al. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil. – 2017. – Vol. 23, N1. – P. 9–19.
      12. Lembo A., Pimentel M., Rao S. et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. – 2016. – Vol. 151, N6. – P. 1113–1121.
      13. Lee O. Y. Asian Motility Studies in Irritable Bowel Syndrome. J Neurogastroenterol Motil. – 2010. – Vol. 16, N2. – P. 120–130.
      14. Krapivnaya O. V. Clinical and prognostic significance of fecal calprotectin in patients with irritable bowel syndrome // Far East Medical Journal. – 2015. – № 4. – Р. 24–27. (in Russian).
      15. Xu D., Gao J., Gillilland M. et al. Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterol. – 2014. – Vol. 146. – P. 484–496
      16. Collignon A., Sandré C., Barc M. C. Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment. Gastroenterol Clin Biol. – 2010. – Vol. 34, S. 1. – P. S71–78
      17. Madsen K. L. Enhancement of epithelial barrier function by probiotics. J Epithel Biol Pharmacol. – 2012. – Vol. 5. – P. 55–59.

    Full text is published :
    Read & Download full text

    1. Central State Medical Academy of the Administrative Department of the President of Russia (Moscow, Russian Federation)

    Keywords:NAFLD, SIBO, intestinal microbiocenosis, endotoxemia, psyllium, rifaximin

    Abstract:Aim of investigation: to study the frequency of occurrence of small intestinal bacterial overgrowth (SIBO) and bacterial endotoxemia (BE) in patients with nonalcoholic fatty liver disease (NAFLD) of different stages. Material and methods: The survey included 100 patients (78 (78%) men, 28 (28%) women) with NAFLD of different stages (steatosis - 30 people, nonalcoholic steatohepatitis (NASH) of minimal activity - 30 people, NASH of moderate activity - 30 people, liver cirrhosis - 10 people) at the average age of 51,83±8,48 years old. SIBO was verified by hydrogen breath test with lactulose (LHBT). BE was diagnosed by method of activated particles with the use of test kits of “MAP-Endotox spp.”, Russia. According to the treatment type patients with NAFLD were divided in 3 groups. The first group of 36 people without SIBO (on the background of lifestyle modification) received a 6-month intake of psyllium. The second group of 35 people with SIBO in addition to lifestyle modification received a 7-day course of rifaximi(7 - days/800 mg/d) and psyllium during the period of observation (6 months). Comparison group to assess the prognosis of the disease consisted of 19 patients with NASH who refused therapy at different stages of the investigation. Results: SIBO was detected in 50% patients, including 38% people with recorded BE. In group of steatosis BE rate did not exceed normal values, in NASH groups it increased to 6.67% and 33.33%, respectively, in cirrhosis group - 70%. We analyzed the effectiveness of antibacterial (rifaximin) and prebiotic (psyllium) therapy in the course of 6 months. It is established that control LHBT and MAP-test after 6-months’ observation showed no SIBO and BE in all patients of two groups. The comparison group without therapy aimed at the normalization of intestinal microbiocenosis displayed negative dynamics in the course of the disease. According to the results of the control tests, the frequency of SIBO in this group increased by 20%. Conclusion: 1. Frequency of detection of intestinal microbiocenosis disorders, established by the results of LHBT and MAP-test, increases with the severity of pathological process that testifies the role of microbiota as one of the most important components in development and progression of NAFLD. 2. Combined course therapy of rifaximin and long-term intake of psyllium is effective for correction SIBO and BE as the control tests determine the normalization of their indicators.

      1. Ivashkin V.T., Drapkina O. M., Maev I. V. et al. Rasprostranennost’ nealkogol’noj zhirovoj bolezni pecheni u pacientov ambulatorno-poliklinicheskoj praktiki v Rossijskoj Federacii: rezul’taty issledovaniya DIREG 2 // RZhGGK. 2015; 25(6):31–41.
      2. Younossi Z.M., Blissett D., Blissett R., Henry L., Stepanova M., Younossi Y., Racila A., Hunt Sh., Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe // Hepatology. 2016 Nov;64(5):1577–1586.
      3. Byrne C.D., Targher G. et al. NAFLD: A multisystem disease // Journal of Hepatology. 2015;62(1):47–64.
      4. Loomba R., Sanyal A. J. et al. The global NAFLD epidemic // Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686–90.
      5. Cua I.H., George J. Non-alcoholic fatty liver disease // Hosp. Med. 2005;66:106–111.
      6. Drapkina O.М., Smirin V. I., Ivashkin V. T. NAZhBP. Sovremennyj vzglyad na problemu // Lechashchij vrach. 2010;5(5):57–61.
      7. Drapkina О.М., Korneeva O. N. Kontinuum nealkogol’noj zhirovoj bolezni pecheni: ot steatoza pecheni do serdechno-sosudistogo riska // Racional’naya farmakoterapiya v kardiologii. 2016;12(4):424–429.
      8. Tilg H., Moschen A. R. et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis // Hepatology. 2010;52(5)
      9. Zvyaginceva T.D., Chernobaj A. I., Gridneva S. V. Kishechnyj mikrobiom i nealkogol’naya zhirovaya bolezn’ pecheni: patogeneticheskiye svyazi i korrekciya probiotikami // Zdorov’ye Ukrainy. 2016;1(39).
      10. Kravchuk Y. A. Kliniko-morfologicheskiye osobennosti steatogepatita alkogol’noj i metabolicheskoj etiologii. Diss. …dokt. med. nauk. – S.-Pb. 2016; 286 s.
      11. Ardatskaya M. D., Bel’mer S. V., Dobrica V. P., Zaharenko S. M., Lazebnik L. B., Minushkin O. N., Oreshko L. S., Sitkin S. I., Tkachenko E. I., Suvorov A. N., Havkin A. I., Shenderov B. A. Disbioz (disbakterioz) kishechnika: sovremennoe sostoyanie problemy, kompleksnaya diagnostika i lechebnaya korrekciya // Eksperimental’naya i klinicheskaya gastrojenterologiya. 2015;117(5):13–50.
      12. Dzhulaj G. S., Shchelochenkov S. V. Mikrobiota zheludochno-kishechnogo trakta v razvitii nealkogol’noj zhirovoj bolezni pecheni // Tverskoj medicinskij zhurnal. 2015;5:41–52.
      13. Fedos’ina E.A., Zharkova M. S., Maevskaya M. V. Bakterial’naya kishechnaya mikroflora i zabolevaniya pecheni. // RZhGGK. 2009;19 (6):73–81.
      14. Kostyukevich O. I. Bylova N. A., Simbirceva A. S. Rol’ kishechnoj mikrobioty v razvitii zabolevanij pecheni i zhelchevyvodyashchih putej. // RMZh. 2016;11:713–20.
      15. Sajjad A., Mottershead M., Syn W. K. et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. // Aliment. Pharmacol. Ther. 2005; 22(4): 291–9.
      16. Zhdanov K. V., Gusev D. A., Zaharenko S. M., Kurtukov M. V., Sukachev V. S. Disbioz kishechnika pri cirroze pecheni // Eksperimental’naya i klinicheskaya gastrojenterologiya. 2011;6:38–44.
      17. Babasheva G. G. Klinicheskoe znachenie endotoksina i lipopolisaharid-svyazyvayushhego belka u bol’nyh nealkogol’noj zhirovoj bolezn’yu pecheni. – Diss. … – Stavropol. 2015; 141 s.
      18. Kljaritskaya I. L., Semenihina E. V. Rol’ IL-8 i LBP v patogeneze sindroma izbytochnogo bakterial’nogo rosta u pacientov s nealkogol’nym steatogepatitom. // Krymskij terapevticheskij zhurnal. 2015;2: 54–60.
      19. Gäbele E., Dostert K., Hofmann C., Wiest R., Schölmerich J., Hellerbrand C., Obermeier F. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH // J Hepatol. 2011 Dec;55(6):1391–9.
      20. Harte A. L., da Silva N. F., Creely S. J., McGee K.C. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease.// J Inflamm. 2010;30:7–15.
      21. Alisi A., Manco M., Devito R., Piemonte F., Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children // J Pediatr Gastroenterol Nutr. 2010; 50(6), 645–649.
      22. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Königsrainer A., Maier K.-P., Bischoff S. C., Bergheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake // J Nutr. 2008 Aug; 138(8):1452–5.
      23. Liu X., Lu L., Yao P., Ma Y., Wang F., Jin Q., Ye X., Li H., Hu F. B., Sun L., Lin X. Lipopolysaccharide binding protein, obesity status and incidence of metabolic syndrome: a prospective study among middle-aged and older Chinese // Diabetologia. 2014;57:1834–1841.
      24. Kucheryavyj Ju.A., Maevskaya E. A., Ahtaeva M. L., Krasnyakova E. A. Nealkogol’nyj steatogepatit i kishechnaya mikroflora: est’ li potencial prebioticheskih preparatov v lechenii? // Medicinskij sovet. Gastrojenterologiya. 2013;3:46–51.
      25. Loginov V. A. Sindrom izbytochnogo bakterial’nogo rosta u bol’nyh so snizhennoj kislotoproduciruyushchej funkciej zheludka (klinicheskoe znachenie, diagnostika i lechenie). – Diss. … – 2015;126 s.
      26. Rusanova E.V., Niyazmatov A. G., Protas I. M. Rol’ jendotoksina v razvitii gnoyno-septicheskih zabolevanij i metody ego vyyavleniya v krovi // Al’manah klinicheskoj mediciny. 2013;2:70–73.
      27. Garbuzenko D. V., Mikurov A. A., Smirnov D. M. Bakterial’naya jendotoksinemiya i risk razvitiya krovotechenij iz varikozno-rasshirennyh ven pishhevoda u bol’nyh cirrozom pecheni // Klinicheskaya medicina. 2012;7:48–51.
      28. Klinicheskie rekomendacii po diagnostike i lecheniyu nealkogol’noj zhirovoj bolezni pecheni Rossijskogo obshchestva po izucheniyu pecheni i Rossijskoj gastroenterologicheskoj associacii / pod red. V. T. Ivashkina. – М. 2015; 38 s.
      29. EASL–EASD–EASO Clinical Practice Guidelines for the Management of Non-alcoholic Fatty Liver Disease // Journal of Hepatology. 2016;64(6):1388–1402.
      30. Ledochowski M., Ledochowski E., Eisenmann A. Hydrogen Breath tests. Innsbruck, 2008;59.
      31. Alisi A., Ceccarelli S., Panera N., et al. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis // Front Cell Infect. Microbiol. 2012;2:132.

    Full text is published :
    Read & Download full text

    1. FSBI «A. N. Ryzhykh State scientific center of coloproctology» of Ministry of health of Russian Federation (Moscow, Russian Federation)

    Keywords:Ultrasonography examination, ulcerative colitis, contrast enhancement, therapy effectiveness

    Abstract:Aim of investigation: determination and selection of parameters of ultrasonography with contrast enhancement for evaluation of the effectiveness of the therapy in patients with ulcerative colitis (UC). Materials and methods: The study included 20 patients with active left-side UC or pancolitis. Before the treatment all patients underwent colonoscopy and ultrasonography in standard regimen and with contrast enhancement. All patients received systemic 5-aminosalicylic acid in granules at a dose of 4 g per day for 3 months. After treatment, patients were repeatedly underwent endoscopy and ultrasound. Based on the ultrasound obtained with a contrast enhancement curve, the contrast parameters were automatically calculated: the maximum intensity (Imax), the area under the contrast curve (AUC), rise time (RT), peak time (TTP) and mean transit time (mTT), time to half-wash (HTWo). Results: According to the results of the examination of patients before and after three months of treatment, it was established that the most informative US-parameter for assessing the activity of inflammation is the AUC. For this parameter, a positive correlation with the endoscopic activity of the UC was obtained. Conclusion: Ultrasonography with contrast enhancement may be a good alternative non-invasive method for assessing the efficacy of conservative therapy in patients with UC, but it is necessary to continue the study on a larger sample to identify the relationship between the other parameters and validate this technique.

      1. Shelygin Yu.A., Blagodarnyy L. A. Spravochnik po koloproktologii. [Reference book on coloproctology]. Moscow, Literra Publ., 2012. 460–522 p.
      2. Ivashkin VT, Shelygin Yu.A., Khalif IL et al. Clinical guide of russian association of gastroenterology and russian Association of coloproctology on diagnostics and treatment of Ulcerative colitis. Koloproktologia 2017;1(59): 6–30
      3. Schnitzler F., Fidder H., Ferrante M. et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease // Inflamm Bowel Dis. - 2009. - № 15. - Р.1295-1301
      4. Baert F., Moortgat L., Van Assche G. et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease // Gastroenterology. - 2010. - № 138. - Р.463-468
      5. Cellier C., Sahmoud T., Froguel E. et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn’s disease. A prospective multicentre study of 121 cases. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives // Gut. - 1994. - № 35. - Р.231-235
      6. Panes J., Bouzas R., Chaparro M. et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease // Aliment Pharmacol Ther. - 2011. - № 34. - Р.125-145
      7. Horsthuis K., Bipat S., Bennink R. J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies // Radiology. - 2008. - № 247. - Р.64-79
      8. Quaia E., Migaleddu V., Baratella E. et al. The diagnostic value of small bowel wall vascularity after sulfur hexafluoride-filled microbubble injection in patients with Crohn’s disease. Correlation with the therapeutic effectiveness of specific anti-inflammatory treatment // Eur J Radiol. - 2009. - № 69. - Р.438-444
      9. Girlich C., Jung E. M., Iesalnieks I. et al. Quantitative assessment of bowel wall vascularisation in Crohn’s disease with contrast-enhanced ultrasound and perfusion analysis // Clin Hemorheol Microcirc. - 2009. - № 43. - Р.141-148
      10. Socaciu M., Badea R., Hagiu C. et al. Ultrasound Assessment Techniques and Quantification of Bowel Inflammation in Several Intestinal Diseases: Initial Experience // Automat Comput Appl Math. - 2009. - № 18. - Р.212-217.
      11. Badea R., Socaciu M., Ciobanu L. et al. Contrast-enhanced ultrasonography (CEUS) for the evaluation of the inflammation of the digestive tract wall // J Gastrointestin Liver Dis. - 2010. - № 19. - Р.439-444.
      12. Ripolles T., Rausell N., Paredes J. M. et al. Effectiveness of contrast-enhanced ultrasound for characterization of intestinal inflammation in Crohn’s disease: a comparison with surgical histopathology analysis // J Crohns Colitis. - 2013. - № 7. - Р.120-128.
      13. Wong D. D., Forbes G. M., Zelesco M. et al. Crohn’s disease activity: quantitative contrast-enhanced ultrasound assessment // Abdom Imaging. - 2012. - № 37. - Р.369-376.
      14. Malago R., D’Onofrio M., Mantovani W. et al. Contrast-enhanced ultrasonography (CEUS) vs. MRI of the small bowel in the evaluation of Crohn’s disease activity // Radiol Med. - 2012. - № 117. - Р.268-281.
      15. Goertz R. S., Heide R., Bernatik T. et al. Mesenteric transit time using contrast-enhanced ultrasound (CEUS) does not correlate with disease activity in Crohn’s disease // Ultraschall Med. - 2012. - № 33. - Р.164-169.
      16. Girlich C., Schacherer D., Jung E. M. et al. Comparison between a clinical activity index (Harvey-Bradshaw-Index), laboratory inflammation markers and quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound in Crohn’s disease // Eur J Radiol. - 2012. - № 81. - Р.1105-1109.
      17. Girlich C., Jung E. M., Huber E. et al. Comparison between preoperative quantitative assessment of bowel wall vascularization by contrastenhanced ultrasound and operative macroscopic findings and results of histopathological scoring in Crohn’s disease // Ultraschall Med. - 2011. - № 32. - Р.154-159.
      18. Ripolles T., Martinez M. J., Paredes J. M. et al. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy // Radiology 2009. - № 253. - Р.241-248.
      19. Migaleddu V., Scanu A. M., Quaia E. et al. Contrast-enhanced ultrasonographic evaluation of inflammatory activity in Crohn’s disease // Gastroenterology. - 2009. - № 137. - Р.43-52.
      20. Kumar P., Domjan J., Bhandari P. et al. Is there an association between intestinal perfusion and Crohn’s disease activity? A feasibility study using contrast-enhanced ultrasound // Br J Radiol. - 2009. - № 82. - Р.112-117.
      21. Serra C., Menozzi G., Labate A. M. et al. Ultrasound assessment of vascularization of the thickened terminal ileum wall in Crohn’s disease patients using a low-mechanical index real-time scanning technique with a second generation ultrasound contrast agent // Eur J Radiol. - 2007. - № 62. - Р.114-121.
      22. De Franco A., Di Veronica A., Armuzzi A. et al. Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity // Radiology. - 2012. - № 262. - Р.680-688.
      23. Girlich C., Schacherer D., Jung E. M. et al. Comparison between quantitative assessment of bowel wall vascularization by contrast-enhanced ultrasound and results of histopathological scoring in ulcerative colitis // Int J Colorectal Dis. - 2012. - № 27. - Р.193-198.
      24. Yamaguchi T., Yoshida S., Tanaka S. et al. Predicting the clinical response to cytapheresis in steroid-refractory or -dependent ulcerative colitis using contrast-enhanced ultrasonography // Scand J Gastroenterol. - 2009. - № 44. - Р.831-837.

    Full text is published :
    Khalif I.L., Shapina M.V.,Orlova L.P., Evgrafov P.G.ULCERATIVE COLITIS TREATMENT EFFICIENCY ASSESSED BY ULTRASONOGRAPHY WITH CONTRAST ENHANCEMENT. Experimental and Clinical Gastroenterology Journal. 2018;153(05):32-37
    Read & Download full text

    1. FSBEI Novosibirsk State Medical University of Ministry of Health of the Russian Federation (Novosibirsk, Russian Federation)
    2. FSBI Novosibirsk Tuberculosis Research Institute of Ministry of Health of the Russian Federation (Novosibirsk, Russian Federation)

    Keywords:abdominal tuberculosis, intestinal tuberculosis, mesenterial lymph node tuberculosis, disseminated pulmonary tuberculosis, HIV-infection, risk groups, diagnosis of abdominal tuberculosis

    Abstract:The goal of the study is determining of the prevalence and morbidity of tuberculosis (TB) lesions in organs of abdominal cavity in pulmonary TB patients during the period of unfavorable epidemic situation (2006-2008 years) and the period of reduction in TB incidence (2015-2017 years). Clinical records of patients with combined pulmonary and abdominal tuberculosis that underwent treatment in TB hospital during the periods of 2006-2008 and 2015-2017 years were analyzed. Despite a reduction in overall TB incidence from 2006-2008 to 2015-2017 years, the proportion of pulmonary TB patients with abdominal tuberculosis, treated in TB hospital, increased for this period almost twice (1,95±0,3% vs 3,5±0,6%). Abdominal tuberculosis is the result of generalization of TB. Abdominal TB was registered more often in 2015-2017 than in 2006-2008 (75,9±7,9% vs 20,5±6,1%, p=0,00001, Fischer exact test) and was less frequently associated with lung tissue destruction (27,4 and 81,8%, respectively, p=0,00001, Fischer exact test). Detection of Mycobacterium tuberculosis in feces increase significantly an efficiency of diagnosis of TB colitis (especially in patients without clinical intestinal symptoms).

      1. Global tuberculosis report 2017. – World Health Organization. [Электронный ресурс] URL: (Дата обращения 28.03.2018).
      2. Rossiiskii statisticheskii iejegodnik, 2016. Federalnaiya slujba gosudarstvennoi statistiki. URL:
      3. Osnovnii pokasateli protivotuberkulosnoi deiatelnosti v Sibirskom I Dalnevostochnom federalnom okruge / Novosibirsk: IPC NGMU, 2017. – 92 s. URL:–2012-gg/metodicheskie-rekomendacii-i-posobija/
      4. Kulchavenia E. V., Jukova I. I. Vnelegochnii tuberkulos – voprosov bolshe, chem otvetov. Tuberkulos i bolesni legkih. 2017. N2. S.59–63.
      5. Sovetova N. A. Savin I. B., Malchenko O. V. i dr. Sovremennaia luchevaia diagnostika vnelegochnogo tuberkulosa. Problemi tuberkulosa i bolesnei legkih. 2006. N11. S. 6–9.
      6. Skopin M. S. Batirov F. A. Kornilova Z. H. Rasprostranennost tuberkulosa organov bruchnoi polosti i osobennosti ego viavlenia. Problemi tuberkulosa i bolesnei legkih. 2007. N1. S. 22–26.
      7. Panteleev A. M. Klinicheskoe predstavlenie o patogenese generalisacii tuberkulosa u bolnih HIV-infekciei. Tuberkulos i bolesni legkih. 2015. N2. S.26–30.
      8. Levashov Iu.N., Mushkin A. Iu., Grishko A. N. Vnelegochnii tuberkulos v Rossii: oficialnaia statistika i realnost. Problemi tuberkulosa i bolesnei legkih. 2006. N11. S. 3–6.
      9. Kiselevich O. K., Balashova N. A., Iusubova A. N., Shirshov I. V. Tuberkulos mnogestvennih lokalisacii u detei rannego vosrasta. Tuberkulos i bolesni legkih. 2015. N6. S.76.
      10. Guseinov A. G., Guseinov G. K. Atipichno tekuchii tuberkuliosnii mezadenit u pacienta s HIV-infekciei, narkomaniei i gepatitom C. Tuberkulos i bolesni legkih. 2015. N11. S.52–55.
      11. Holtobin D. P., Jukova I. I., Brijatiuk E. V. i soavt., Demograficheskie i klinicheskie osobennosti urogenitalnogo tuberkulosa na sovremennom etape. Sibirskii meicinskii vestnik. 2017. N1. S. 9–15.
      12. Barinov V. S., Prohorovich N. A. Differencialnaia diagnostika abdominalnogo tuberkulosa na osnove kliniko-laboratornih i laparoskopicheskih dannih: Posobie dlia ftisiatrov i hirurgov. – SPb., 1997. – S.4–6.
      13. Perelman M. I., Bogadelnikova I. V. Ftisiatria. Uchebnik. «GEOTAR-Media», 2010. – 266 s.

    Full text is published :
    Poddubnaya L.V.,Zyryanova T.V.,Petrenko T.I.,Kononenko V.G. et al. ABDOMINAL TUBERCULOSIS IN PULMONARY TUBERCULOSIS PATIENTS. Experimental and Clinical Gastroenterology Journal. 2018;153(05):38-43
    Read & Download full text

    1. FSBI “SFSCC FMBA of Russia” (Novosibirsk, Russian Federation)
    2. SBEI HPE “Siberian State medical University of Minzdrav of Russia” (Novosibirsk, Russian Federation)

    Keywords:irritable bowel syndrome, psychovegetative status, drug-free rehabilitation, SMC-therapy, EHF-therapy

    Abstract:Complex of rehabilitation measures at persons of young age with clinical signs of irritable bowel syndrome using SMC-therapy and EHF-therapy, which was prescribed based on the type of functional disorders, contributes to a significant improvement of clinical and laboratory parameters in the form of relief of complaints and symptoms against the background of increasing adaptive capacity and normalization of psycho-autonomic status. The direct effectiveness of non-pharmacological rehabilitation amounted to 94.4% of constipation and 93.3% in diarrhea. The obtained results were associated with the peculiarities of rehabilitation facilities (χ2=to 34.94; p=0,004; r=0,45;), while the maximum contribution to the total statistics Pearson correlations were “significant improvements” and “improvements” with the rehabilitation complexes, including SMT-therapy and EHF-therapy (with diarrhea - χ2=3,59 and χ2=1,51; constipation - χ2=2,85 and χ2=1,37, respectively).

      1. Ivashkin V. T., Shelygin Y. A., Marshall, E. K., and others. Clinical guidelines of the Russian gastroenterological Association, Association of Coloproctology Russia on the diagnosis and treatment of patients with irritable bowel syndrome. Grew. Sib. of gastroenterology. hepatol. coloproctol. – 2014.-№ . 2. – P. 92–102.
      2. Samsonov A. A. Features of patients with irritable bowel syndrome, based on polyvalence of the disease background. Gastroenterology. – 2014.-№ 2. – P. 26–30
      3. Maev I. V., Cheremushkin S. V. irritable bowel Syndrome. Manual for doctors. – Moscow: “Forte-print”, 2012. – P. 6
      4. Loranskaya I. D., Kozlova Yu. A. The role of vegetative disorders in the pathogenesis of irritable bowel syndrome. Experimental and clinical gastroenterology. – 2014. – Issue 107, № 7. – P. 87–90.
      5. Stanislavchuk N. A. Kulchytska E. N. Features of the functional state of the autonomic nervous system in patients with irritable bowel syndrome. Pathogenesis. – 2013. – Vol. 11, № 3. – P. 74–77.
      6. Kozlov Yu. A. Irritable bowel Syndrome: clinical significance of autonomic status with refractory disease. The dissertation on competition of a scientific degree of candidate of medical Sciences. – Moscow, 2015. – 24p.
      7. Poluektova E. A., Kuchumova S. Yu., Shifrin O. S., Sheptulin A. A., Ivashkin V. T. Pathogenic role of intestinal microflora changes in patients with irritable bowel syndrome and the ways of its correction. Grew. Sib. of gastroenterology. Hepatol. coloproctol. – 2014. – № 3. – P. 89–96.
      8. Prikhodko E. M., Tsurtsumia D. B., Seliverstov P. V., Sitkin S. I., Radchenko V. G. The possibilities of modern therapy for patients with irritable bowel syndrome. Attending physician. – 2016. – № 8. – P. 76–80.
      9. Poluektova E. A., kuchumova S. Yu., Sheptulin A. A., Ivashkin V. T. Treatment of irritable bowel syndrome from the standpoint of modern ideas about the pathogenesis of the disease. Grew. Sib. of gastroenterology. Hepatol. coloproctol. – 2013. – № 1. – P. 57–64.
      10. Akhmedov V. A., Orlov I. N., Gaus, O. V. Modern methods of rehabilitation of patients with irritable bowel syndrome. Therapy. – 2017. – № 3. – P. 49–55.
      11. Danilov D. S., Morozova V. D., Korobkova I. G., Lukyanova T. V. Irritable bowel Syndrome in the practice of psychiatrist (the problem of nosological independence) and the possibility of its treatment with antidepressants (for example, the effectiveness of paroxetine). Neurology, neuropsychiatry, psychosomatics. – 2013. -№ 2. – P. 46–50.
      12. Lagunova N. In. Marchukova A. Yu., Lebedeva T. N. Application of frequency-resonance therapy in health-resort rehabilitation of children with irritable bowel syndrome. Bulletin of Belgorod state University. – 2017. – Volume 37, № 5 (254). – P. 52–58.
      13. Filimonov R. M., Faustova I. I., Filimonova T. R. Physical therapy in the irritable bowel syndrome. Issues of balneology, Physiotherapy and therapeutic physical training. – 2013.-№ 25. – P. 51–56.
      14. Filippova O. L., Statsenko E. V., Bikbova G. R., Labutina N. Sazonova E. I. Irritable bowel syndrome. The possibility of physical therapy. Sanatorium and resort organization: management, marketing, economics, finance. – 2015. – № 4. – P. 68–73.
      15. Abramovich S. G.(ed.), Kulikov A. G. Physiotherapy in Clinical gastroenterology. Part 1: practice benefit. Irkutsk: RIO GBOU DPO IGMAP, 2016. – 52 p.
      16. Kasinova A. C., Tekeeva F. I., Prosolenko B. A., Kazaryan T. S. Sanatorium-resort treatment of patients with irritable bowel syndrome. Spa medicine. – 2015. – № 2. – P. 104–107.
      17. Kazaryan T. S. Balneophysiotherapy of irritable bowel syndrome. Spa medicine. – 2016. -№ 1. – P. 63–67.
      18. Litvinova O. N. Physiotherapeutic methods used in the complex treatment of patients with chronic constipation in large intestine abnormalities. Physiotherapy, balneology and rehabilitation. – 2016. – Volume: 15, № 4. – P. 182–184.
      19. Efimenko N. I., Kazaryan T. S., Khapaeva F. M., Chalaya E. N. Dynamic electroneurostimulation in the complex sanatorium treatment of patients with irritable bowel syndrome with constipation. Physiotherapy, balneology and rehabilitation. – 2016. – Volume 15, № 2. – 86–91.
      20. Orda, T. A., P. V. Poruchikov, V. F. Horde Wave therapy. Occupational medicine. M.: Eksmo, 2008. – № 12. – P. 136,430.
      21. Poddubnaya O. A., Ugolnikov O. I., Levitskaya T. E. Chronophototherapy patients with dysfunctions of the gallbladder and dyscholia on the background of psycho-vegetative imbalance. Physiotherapy, balneology and re-habilitation. – 2014. – № 3. – P. 12–17.
      22. Rapoport S. I., Frolov V. A., Khetagurov L. G. Chronobiology and chronomedicine. Guide. M.: OOO “Medical in-formation Agency”, 2012. – P. 72.
      23. Garkavi L. H., Kvakina E. B., Kuzmenko T. S. Antistress reactions and activation therapy. M.,”IMEDIS”, 1998. – P. 28
      24. Wayne A. M., Solov’eva, A. D., Danilov A. B., Khaspekov N. B. Methods of study of vegetative nervous system. Vegetative disorders. – Moscow, 2003. – P. 752.

    Full text is published :
    Poddubnaya O.A.,Privalova N.I. THE EFFICIENCY OF THE COMPLEX NON-DRUG REHABILITATION OF YOUNG PATIENTS WITH IRRITABLE BOWEL SYNDROME. Experimental and Clinical Gastroenterology Journal. 2018;153(05):44-51
    Read & Download full text

    1. Scientific Сentre for Family Health and Human Reproduction Problems (Moscow, Russian Federation)

    Keywords:men, women, eubiosis, intestinal dysbiosis

    Abstract:Aims. Analyze the structure of intestinal dysbiosis in adults, taking into account gender differences. Materials and methods: in the period from 2013 to 2017 the coprological material from 572 patients aged from 22 to 74 years (134 men and 438 women) was studied. Results: Long-term studies have shown that more than 90% of the adult population observed dysbiotic changes of varying severity. The structure was dominated by mild and moderate disorders (I and II degree of dysbiosis). In women, on average, more often than in men, there were dysbiotic changes of I degree (in 67,1±2,2% and 58,2± 4,2%, respectively), the proportion of men with dysbiotic disorders of II and III severity was higher than in women. It was revealed that in men in 2017 there was a decrease in the frequency of registration of the II degree of dysbiosis to 10,5± 7,0%, but the number of severe dysbiotic disorders of the III degree increased (to 10,6±7,0%) (p<0,05). In 2015 and 2017 men’s and, in 2016, the women there was not a single case eubioz intestine. This circumstance can be connected both with decrease in a standard of living, and with the ecological pressure on an organism of negative factors of environment continuing in our territory.

      1. Global status report on non communicable diseases 2010; 1, Chronic disease – prevention and control. 2. Chronic disease – epidemiology 3. Chronic disease – mortality 4.Cost of illness. 5. Delivery of health care. World Health Organization. ISBN978 92 456422 6 (NLM classification: WT 500). Available at:
      2. Wang YR, Richter JE, Dempsey DT. Trends and Outcomes of Hospitalizations for Peptic Ulcer Disease in the United States, 1993 to 2006. Journal: Annals of Surgery Ann Surg. – 2010. – Т. 251, № 1. –С.51–58
      3. Lazebnik L. B., Masharova A. A., Bordin D. S., Vasil’ev Yu.V. et al. Rezul’taty mnogotsentrovogo issledovaniya «Epidemiologiya gastroezofageal’noy reflyuksnoy bolezni v Rossii» (MEGRE). Terapevticheskiy arkhiv. – 2011. – № 1. – S.45–50.
      4. Eganyan R. A., Kalinina A. M., Ipatov P. V., Drapkina O. M. Metodologicheskie aspekty i rezul’tativnost’ vyyavleniya zabolevaniy organov pishchevareniya pri dispanserizatsii vzroslogo naseleniya. Profilakticheskaya meditsina. – 2017. – № 1. – S.15–23
      5. Kostyukevich O. I. Vliyanie kishechnoy mikroflory na zdorov’e cheloveka. Ot patogeneza k sovremennym metodam korrektsii disbioza. RMZh. – 2011. – T. 19, № . 5. – S. 304–308
      6. Bellantani S., Saccoccio G., Masutti F., Croce LS. et al. Prevalence and risk factors for hepatic steatosis in northern Italy. Ann. Intern. Med. – 2000. –№ 132. – С. 112–117.
      7. Chikhacheva E. A., Seliverstov P. V., Teterina L. A., Dobritsa V. P. et al. Mikrobiotsenoz kishechnika pri khronicheskikh zabolevaniyakh pecheni: diagnostika i lechenie. Vrach. – 2011. – № . 7. – S. 18–21
      8. Bondarenko V. M., Matsulevich T. V. Disbakterioz kishechnika kak kliniko-laboratornyy sindrom: sovremennoe sostoyanie problemy. – M.: GEOTAR – Media, 2007. –S. 8–35.
      9. Sukhareva I. A. Sravnitel’naya kharakteristika zabolevaemosti, smertnosti i ozhidaemoy prodolzhitel’nosti zhizni muzhchin i zhenshchin v respublike Krym. Meditsinskiy al’manakh. – 2016. – № 1 (41). – S. 14–17
      10. Semutenko K. M., Cheshik I. A., Sharshakova T. M. Osnovnye faktory, opredelyayushchie sostoyanie zdorov’ya muzhchin. Voprosy organizatsii i informatizatsii zdravookhraneniya. – 2014. – № 2. – S.36–46.
      11. Ardatskaya M. V., Bel’mer S.V., Dobritsa V. P., Zakharenko S. M. et al. Disbioz (disbakterioz) kishechnika: sovremennoe sostoyanie problemy, kompleksnaya diagnostika i lechebnaya korrektsiya. Experimental’naya i klinicheskaya gastroenterologia – 2015. – № 5. – S. 13–50
      12. Ofitsial’nyy sayt Territorial’nogo organa Federal’noy sluzhby gosudarstvennoy statistiki po Irkutskoy oblasti. Available at:
      13. Popkova S. M., Rakova E. B., Kichigina E. L., Nemchenko U. M. et al. Mikroekologicheskiy peyzazh u detey Irkutskoy oblasti na fone gigienicheskikh kharakteristik territorii. Izvestiya Irkutskogo gosudarstvennogo universiteta. Seriya: Biologiya. Ekologiya. – 2012. – № 5(4). – S.44–54.
      14. Krasnozhenov E. P., Akhremenko Ya. A. Kolonizatsionnaya rezistentnost’ organizma cheloveka v norme i pri patologii. Monografiya. – Kirov: MTsNIP, 2013. – S.115
      15. Savilov E. D., Il’ina S. V. Infektsionnaya patologiya v usloviyakh tekhnogennogo zagryazneniya okruzhayushchey sredy: klinikoepidemiologicheskie issledovaniya. – Novosibirsk: Nauka, 2010. – 248 s.
      16. Nemchenko U. M., Rakova E. B., Popkova S. M., Savel’kaeva M.V. et al. Struktura disbiozov kishechnika u detey doshkol’nogo vozrasta za mnogoletniy period nablyudeniy. Klinicheskaya laboratornaya diagnostika. – 2015. – T. 60, № 2. – S. 63–65
      17. Ivanova E.I., Rychkova L. V., Nemchenko U. M., Bukharova E. V., Savelkaeva M. V., Dzhioev Y. P. The structure of the intestinal microbiota of the intestine and the frequency of detection of pathogenicity genes (stx1, stx2, bfp) in Escherichia coli with normal enzymatic activity isolated from children during the first year of life. Molecular Genetics, Microbiology and Virology. – 2017. – Т. 32, № 1. – С. 42–48.
      18. Kozlova I. V., Pakhomova A. L. Sovremennyy patsient gastroenterologicheskogo profilya: shtrikhi k klinicheskomu portretu. Experimental’naya i klinicheskaya gastroenterologia. – 2015. –Vypusk 118. № 6. – S.4–10

    Full text is published :
    Nemchenko U. M., Ivanova E. I., Grigorova E.V, Voropaeva N. M. et al. CHANGES IN THE STRUCTURE OF THE DYSBIOSIS OF THE INTESTINE IN THE ADULT POPULATION FOR LONG-TERM OBSERVATION PERIOD. Experimental and Clinical Gastroenterology Journal. 2018;153(05):52-56
    Read & Download full text

    1. Moscow clinical scientific and practical center. A. I. Loginov (Moscow, Russian Federation)

    Keywords:constipation, dolichosigma, electromyography, motor bowel function

    Abstract:Irritable bowel syndrome (IBS) is a functional bowel disease in which recurrent abdominal pain is associated with defecation or a change in bowel function. Despite the numerous works devoted to the study of mechanisms of IBS development, intestinal motility in this disease has not been studied enough. The goal is to identify features of the motor function of the colon and small intestine in irritable bowel syndrome with constipation (IBS-C) and dolichosigma. Material and methods. The method of electromyography was used to study 84 patients with IBS-C in comparison with a group of 25 patients with dolichosigma and a group of 35 patients with functional constipation. The frequency of slow waves of the small and large intestine (patients with functional constipation) and left colon (patients with IBS-C and dolichosigma) was measured by the hardware-software complex “Conan-M”. Results and discussion. In electromyography patients with IBS-C showed a decrease in the frequency of slow waves to 5.4±0.2 V min (10%, p<0.05), the amplitude - to 0.09±0001 mV (46.6% p<0.05). The increase of spike activity was revealed: frequency 2.8±0.18 (40% p<0.05)., amplitude-0.13±0.02 mV (13.4% p<0.05). In patients with dolichosigma on electromyography revealed a decrease in the frequency of slow waves to 4.8±0.15 per minute (20%, p<0.05), the amplitude - to 0.07±0011 mV (53.3% p<0.05) with minimal spike activity. IBS-W is characterized by hypomotor dyskinesia of the left parts with pronounced spastic contractions of the smooth muscles of the circular layer of the intestine due to, perhaps, the activity of stimulating serotoninergic effects on the spastic activity of the circular muscle layer or inhibitory adrenergic neurons of the intermuscular (auerbachian) nerve plexus. When dolichosigma identified hypomotor dyskinesia of the left departments of the colon due to stretching of the mechanoreceptors in the afferent neurons of the intramural reflex arcs.

      1. Tokmulina G. M., et al. «Roman criteria for the IV syndrome of irritable bowel: the evolution of views on pathogenesis, diagnosis and treatment.» Lech the doctor «2017; 3: 61–67.
      2. Gershon M.D, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 2007; 132:397-414.
      3. Hoffman J.M, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012; 142:844-854
      4. Stasi C, Bellini M, Bassotti G, Blandizzi C, Milani S. Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol. 2014;18(7):613-21
      5. Beattie D. T., Smith J. A. Serotonin pharmacology in the gastrointestinal tract: a review.Naunyn Schmiedebergs. Arch. Pharmacol. 2008; 377, 181-203.
      6. Ladabaum U. Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications. Aliment. Pharmacol. Ther. 2003;17, 1021-1030.
      7. Kim J.J, Khan W.I. 5-HT7 receptor signaling: improved therapeutic strategy in gut disorders. Front Behav Neurosci. 2014;11;8:396
      8. Meuser T., Pietruck C., Gabriel A., Xie G.-X., Lim K.-J., Pierce Palmer P. 5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci.2002; 71, 2279-2289.
      9. Zou B. C., Dong L., Wang Y., Wang S. H., Cao M. B. Expression and role of 5-HT7 receptor in brain and intestine in rats with irritable bowel syndrome. Chin. Med. J. (Engl) 2007; 120, 2069-2074.
      10. Lychkova A. E. Coordination of the myoelectrical activity of the large and small intestine. Experimental and Clinical Gastroenterology Journal. 2012;3:59–
      11. Lychkova A. E., Puzikov A. M. The digestive tract motility and nutritional support with postgastroresectional syndrome. Experimental and Clinical Gastroenterology Journal. 2015;120(8):25–29.
      12. Mayev I. V., Samsonov A. A., Nikushkin I. N., Ivashkina N. Yu. Irritable bowel syndrome, relevance of problem and issues of modern therapy. 2011;2:18–25
      13. Clarke G, Quigley EM, Cryan JF, et al. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med 2009;15:478-89
      14. Poluektova V. A. Pain in the abdomen with functional bowel disorders. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2001;2:27–33
      15. Ардатская М. Д., Топчий Т. Б. Абдоминальная боль и висцеральная гиперчувствительность пациентов с синдромом раздраженного кишечника. Римские критерии IV и клиническая практика.

    Full text is published :
    Lychkova A. E., Ruchkina I. N., Poleva N. I., Puzikov A. M. MOTOR FUNCTION OF THE INTESTINE IN IRRITABLE BOWEL SYNDROME WITH CONSTIPATION. Experimental and Clinical Gastroenterology Journal. 2018;153(05):57-60
    Read & Download full text

    1. Acad. E. A. Wagner Perm State Medical University (Perm, Russian Federation)

    Keywords:S. aureus, C. albicans. colonic biotope, antagonism, microbiota

    Abstract:Intestinal microflora is considered as the main determinant of human health and disease. There is evidence that changes in the relationship between the composition of intestinal microbiota and the human body can be accompanied by the development of allergic and immunopathological conditions, as well as a number of diseases. The aim of the investigation was to assess changes in the lumen of the microbial composition of the large intestine in the case of isolation of S. aureus and C. albicans. Results. In the case of the presence of S. aureus a decrease in the frequency of isolation of typical variants of E. coli. This activity of S. aureus is suppressed by Candida, when the occurrence of E. coli corresponds to the level of the control group. In the presence of C. albicans alone, there is a slight decrease in the allocation of typical E. coli variants. Conclusion. The presence of C. albicans eliminates S. aureus antagonistic relationship with E. coli. On the other hand, the presence of S. aureus and C. albicans both individually and jointly contribute to the development of atypical variants of E. coli. Thus, the studies have shown that the detection of S. aureus and/or C. albicans in the large cell biotope can significantly change the composition of the microbiota, which may affect the functional activity of the colon mucosa and the whole human body.

      1. Bulatova E. M., Bogdanova N. M. Intestinal microflora is one of the factors in the formation of human health. Medical Council. 2013; 1: 30–33.
      2. Simonova E. V., Ponomareva O. A. The role of normal microflora in maintaining human health. The Siberian Medical Journal. 2008; 8: 20–25.
      3. Klaerner H. G., Uknis M. E., Acton R. D., Dahlberg P. S., Carlone-Jambor C., Dunn D. L. Candida albicans and Escherichia coli are Synergistic Pathogens during Experimental Microbial Peritonitis. Journal of Surgical Research. – 1997. – Vol. 70(2). – P. 161–165.
      4. De Brucker K., Tan Y., Vints K., De Cremer K. et al. Fungal β-1,3-glucan increases ofloxacin tolerance of Escherichia coli in a polymicrobial E. coli/Candida albicans biofilm. Antimicrobial Agents and Chemotherapy. – 2015. – Vol. 59(6). – P. 3052–3058.
      5. Morales D. K., Hogan D. A. Candida albicans Interactions with Bacteria in the Context of Human Health and Disease. PLOS Pathogens. – 2010. – № 6 (4). Volume 6 (4). – P. 1–4.
      6. Bandara H. M. H. N., Yau J. Y. Y., Watt R. M. et al. Escherichia coli and its lipopolysaccharide modulate in vitro Candida biofilm formation. Journal of Medical Microbiology. – 2009. – № 12 (58). – P. 1623–1631.
      7. Diebel L. N., Liberati D. M., Diglio C. A. et al. Synergistic effects of Candida and Escherichia coli on gut barrier function. Journal of Trauma and Acute Care Surgery. – 1999. – № 6 (47). – P. 1045–1051.
      8. Chadwick P., Niell M. Transferable antibiotic resistance in E. coli and Klebsiella pneumoniae. Canadian Medical Association Journal. – 1973. – Vol. 109(8). – P. 691–696.
      9. Melo T. A., Dos Santos T. F., De Almeida M. E. et al. Inhibition of Staphylococcus aureus biofilm by Lactobacillus isolated from fine cocoa. BMC Microbiology. – 2016. – Vol. 16. – P. 250–9.
      10. Wang J., Zhang R., Zhou L. et al. Lactobacillus inhibit adhesion of Staphylococcus aureus to HeLa cells. Sheng Wu Gong Cheng Xue Bao. – 2012. – Volume 28 (6). – P. 715–725.
      11. Haileselassie Y., Navis M., Vu N. et al. Lactobacillus reuteri and Staphylococcus aureus differentially influence the generation of monocyte‐derived dendritic cells and subsequent autologous T cell responses. Immunity, Inflammation and Disease. – 2016. 4(3). – P. 315–326.
      12. Karska-Wysocki B., Bazo M., Smoragiewicz W. Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus (MRSA). Microbiological Research. – 2010. – № 165 (8). – P. 674–686.
      13. Godovalov A. P., Bykova L. P., Nikulina E. A., Ozhgibesov G. P. Study of the microbial landscape of the large intestine in candidiasis. MIA Medical Bulletin. 2016; 1 (80): 41–43.
      14. Godovalov A. P., Bykova L. P., Nikulina E. A., Ozhgibesov G. P. et al. Identification of Staphylococcus aureus in the course of a change in the microbiocenosis of the colon. Experimental and Clinical Gastroenterology Journal. 2016; 12 (136): 36–38.
      15. Godovalov A. P., Karpunina N. S., Karpunina T. I. Microbiota of the intestine and vagina of women with secondary infertility and diseases of the gastrointestinal tract. Experimental and Clinical Gastroenterology Journal. 2016; 6 (130): 109–113.

    Full text is published :
    Godovalov A. P., Antonyan A. A., Gorbunova E. A. PECULIARITIES OF MICROFLORA OF THE COLONIC BIOTOPE COLONIZED BY S. AUREUS AND C. ALBICANS. Experimental and Clinical Gastroenterology Journal. 2018;153(05):61-65
    Read & Download full text

    1. The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia (Moscow, Russian Federation)

    Keywords:microbiota, gerontology, gas chromatography-mass spectrometry, microbial markers

    Abstract:Purpose of research. To study the characteristics of the wall of the intestinal microbiota of elderly persons with multiple organ pathology. Materials and methods. 94 patients aged from 55 to 65 years with various somatic pathology were examined. Results. The study of mass spectrometry of microbial markers in blood plasma (near-wall microbiota) in elderly compared to young allowed to establish the following: total number of microbial markers reduced by 40%; good microbiota reduced by 46%; the proportion of opportunistic pathogenic bacteria significantly increased (older people 48%, and in young only 34%); the share of anaerobic microorganisms localized mainly in the large intestine has decreased; the relationship between individual representatives of the microflora has changed.

      1. Hawrelak J.A., Myers S. P. The causes of intestinal dysbiosis: a review // Altern. Med. Rev., 2004, vol. 9, pp. 180–197.
      2. Valenkevich, L.N. (1987). Gastroenterologiia v geriatrii. Pishchevaritel’naia Sistema pri pishchevarenii [Gastroenterology in geriatrics. Digestive system for digestion]. Leningrad: Meditsina.
      3. D’Imperio N. et al. Studio morfometrico-funsionaledell, intestine tenue nel soggetto anziano // G. Clin. Med., 1984, № 9–10, pp. 419–425.
      4. Etingen, L.E. (2003). Normal’naia morfologiia starcheskogo vozrasta [Normal morphology of senile age]. Moskva.
      5. Tkachenko, E.I., Suvorova, A.N. (2009). Disbioz kishechnika. Rukovodstvo po diagnostike I lecheniiu [Intestinal dysbiosis. A guide to diagnosis and treatment]. (2nd ed.). Sankt-Peterburg: InformMed.
      6. Nemtsov, V.I. (2010). Narusheniia sostava kishechnoi mikroflory i metabolicheskii sindrom [Disorders in the composition of the intestinal microflora and metabolic syndrome]. Kliniko-laboratornii konsilium, (1), 4–13.
      7. Konev, Yu.V. (2004). Disbioz v pozhilom i starcheskom vozraste [Disbiosis in elderly and senile age]. Consilium Medicum, (12), 906–909. [Online] Available:
      8. Samsonova, N.G., Zvenigorodskaia, L.A., Cherkashova, E.A. [et. al.], (2010). Disbioz kishechnika i aterogennaia dislepidemiia [Intestinal disbiosis and atherogenic dyslipidemia]. Eksperimental’naia i klinicheskaia gastroenterologiia, (3), 88–94.
      9. Shilov, A.M., Mar’yanovskii, A.A., Petrukhina, N.B. (2013). Endobiotsenoz kishechnika i metabolicheski-assotsiirovannyye sostoyaniia [Endobiocenosis of the intestine and metabolic associated conditions]. Lechebnoe delo, (2), 67–74.
      10. Albert M.A., Danielson E., Rifai N. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study // JAMA, 2001, 286, pp. 64–70.
      11. Mayanskii, A.N. (1999). Mikrobiologiia dlia vrachei [Microbiology for doctors]. Nizhnii Novgorod: NGMA.
      12. Osipov, G.A., Fedosova, N.F., Liadov, K.V. (2007). Kolichestvennyi in situ mikrobiologicheskii analiz po lipidnim markeram v biologicheskikh zhidkostyakh s ispol’zovaniem metoda gazovoi khromatografii – mass spektrometrii [Quantitative in situ microbiological analysis of lipid markers in biological fluids using Gas Chromatography-Mass Spectrometry]. Zdravookhraneniye i meditsinskiye tekhnologii, (5), 20–23.
      13. Kinross J., von Roon A. C., Penney N. et al. The gut microbiota as a target for improved surgical outcome and improved patient care // Curr. Pharm. Des., 2009, 15(13), pp. 1537–1545.
      14. Fedosova, N.F., Liadov, K.V., Osipov, G.A. (2010). Novyye podkhody k analizu infektsionnykh posleoperatsionnykh i posttravmaticheskikh oslozhnenii [New approaches to the analysis of infectious postoperative and post-traumatic complications]. Infektsii v khirurgii, 8(2), 56–62.
      15. Andreitseva, O.I., Kiselev, V.V., Boiko, N.B. [i soavt.] (2010). Mikroekologicheskii status kandidatov na peresadku pecheni [Microecological status of candidates for liver transplantation]. Transplantologiia, (3).
      16. Luckey T. D. Overview of gastrointestinal microecology // Nahrung, 1987, vol. 31, № 5–6, pp. 359–364.
      17. Suau A., Bonnet R., Sutren M. et al. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut // Appl. Environ. Microbiol., 1999, vol. 65, № 11 pp. 4799–4807.
      18. Veiant, R., Moss, U., Khollis, D. [i soavt.] (1999). Opredelitel' netrivial'nykh patogennykh gramotritsatel'nykh bakterii [The determinant of non-trivial pathogenic gram-negative bacteria]. Moskva: Mir. 612–783.
      19. Osipov, G.A., Demina, A.M. (1996). Khromato-mass-spektrometricheskoye obnaruzheniye mikroorganizmov v anaerobnykh infektsionnykh protsessakh [Chromato-mass-spectrometric detection of microorganisms in anaerobic infectious processes]. Vestnik RAMN, 13(2), 52–59.
      20. White D. C. Validation of quantitative analysis for microbial biomass, community structure, and metabolic activity // Adv. Limnol., 1988, № 31, pp. 1–18.
      21. Konev, Iu.V. [i soavt.] (2001). [Dysbiosis in elderly and senile age]. Klinicheskaia gerontologiia, (9), 7–12.
      22. Lazebnik, L.B., Drozdov, V.N. (2003). Zabolevaniia organov pishchevareniia u pozhilykh [Diseases of the digestive system in the elderly]. Moskva: Anakharsis.
      23. Shenderov, B.A. (1998). Meditsinskaia mikrobnaia ekologiia i funktsional'noye pitaniye. Sotsial'no-ekologicheskiye i klinicheskiye posledstviia disbalansa mikrobnoi ekologii cheloveka i zhivotnykh [Medical microbial ecology and functional nutrition. socio-ecological and clinical consequences of imbalance of microbial ecology of humans and animals]. Moskva: GRANTIE, 2.
      24. Dubinin, A.V., Babin, V.N. (1991). Troficheskiye, reguliatornyye sviazi kishechnoi mikroflory i makroorganizma [Trophic, regulatory connections of the intestinal microflora and macroorganism]. Klinicheskaia meditsina, (7), 24–31.

    Full text is published :
    Rodionov G. G., Shantyr I. I., Kolobova E. A., Svetkina E. V. FEATURES OF THE PARIETAL INTESTINAL MICROBIOTA OF THE ELDERLY MEN OF SAINT-PETERSBURG. Experimental and Clinical Gastroenterology Journal. 2018;153(05):66-72
    Read & Download full text

    1. Federal research center “Krasnoyarsk scientific center” Siberian branch of the Russian Academy of Sciences Research Institute of Medical Problems of the North (Krasnoyarsk, Russian Federation)
    2. Krasnoyarsk regional clinical cancer center named. A. I. Kryzhanovsky (Krasnoyarsk, Russian Federation)

    Keywords:neutrophilic granulocytes; chemiluminescence; rectal cancer

    Abstract:The purpose of our work is to study the spontaneous and induced chemiluminescent activity of neutrophilic granulocytes (NG) in patients with rectal cancer in dynamics. Materials and methods. The study included 56 patients with rectal cancer. At the first stage there were 9 people, in the II stage 19 people, on the III 17 and at the IV stage 11 patients. The object of study are neutrophilic granulocytes isolated from venous blood. The control group consisted of 112 healthy blood donors. The intensity of synthesis of active oxygen species of NG was determined by the method of chemiluminescence analysis. Results. The study showed a significant increase in the intensity of spontaneous and induced luminescence and the area under the curve of spontaneous chemiluminescence in the II-IV stages of the disease. When studying zymosan-induced chemiluminescence, the area under the curve is increased in all groups of patients, while in patients at stage IV the total production of reactive oxygen species (ROS) is significantly higher than in stages I and II. On the 7th day after the surgical treatment, the intensity of spontaneous chemiluminescence remains elevated only in patients at the IV stage of the rectal cancer. The intensity of induced chemiluminescence and the area under the curve of spontaneous and induced luminescence are increased at all stages of the disease with respect to control. The activation index was increased in patients at all stages of with rectal cancer both before and after surgery. Сonclusion. As a result of the study, an increase in the intensity of ROS synthesis in patients with rectal cancer was revealed. The total production of reactive oxygen species is higher in the late stage of the disease. An increase in the activation index of neutrophils in all stages of the RPC characterizes the metabolic capabilities of neutrophils to the enhanced synthesis of ROS in functional activation.

      1. Гордеев С.С., Барсуков Ю. А., Ткачёв С. И. и соавт. Местнораспространенный рак прямой кишки (мррРПК): определение, классификация, современные методы лечения // Вестник московского онкологического общества. -2014, -№ 2 -с.2-6.
      2. Балканов А.С., Гуров А. Н., Катунцева Н. А., Белоусова Е. А. Заболеваемость раком прямой кишки населения Московской области в 2010-2014 гг // Альм клин мед. -2016. -№ 44 (5). -С. 599-605.
      3. Райков Н.С., Чупин Р.Н., Попов И. Н. и соавт. Рак прямой кишки // Тюменский медицинский журнал. -2010. -№ 3-4. - С. 75-77.
      4. Нестерова И.В., Ковалева С.В, Чудилова Г. А. и соавт. Двойственная роль нейтрофильных гранулоцитов в реализации противоопухолевой защиты // Иммунология. -2012. -№ 5. - С. 281-285.
      5. Мальцева В.Н., Сафронова В. Г. Неоднозначность роли нейтрофила в генезе опухоли // Цитология. -2009. -Т. 51, № 6. -С. 467-474.
      6. Fridlender Z.G., Albelda S. M. Tumor-associated neutrophils: frend or foe? // Carcinogenesis. -2012. -Vol.33, no. 5. -Р. 949-955.
      7. Finisguerra V., Di Conza G., Di Matteo M. et аl. MET is required for the recruitment of anti-tumoral neutrophils // Nature. -2015. -Vol. 522, no. 7556. -P. 349-353.
      8. Swierczak A., Mouchemore K. A., Hamilton J. A., Anderson R. L. Neutrophils: important contributors to tumor progression and metastasis // Cancer Metastasis Rev. - 2015. -Vol. 34(4), - Р.735-751.
      9. Грачева Т. А. Совершенствование хемилюминесцентного метода исследования функциональной активности фагоцитирующих клеток // Клиническая лабораторная диагностика. -2008. -№ 2. -С. 54-55.
      10. Di Carlo E., Forni G., Lollini P. L., Colomobo M. P. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions // Blood. - 2001. -Vol. 97(2): - Р. 339-345.
      11. Кит О. И., Франциянц Е. М., Никипелова Е. А., Комарова Е. Ф. Состояние свободнорадикальных процессов в ткани злокачественной опухоли толстой кишки // Сиб. мед. обозрение. -2014. -№ 1. -С. 30-34
      12. Prestwich R.J., Errington F., Hatfield Р., Roodman D. G. The immune system - is it relevant to саnсеr development, progression and treatment? // Clin. Oncol. -2008. -Vol. 20. -Р. 101-112.
      13. Коленчукова О.А., Савченко А. А., Смирнова С. В. Особенности нейтрофильных гранулоцитов у больных хроническим риносинуситом // Медицинская Иммунология. -2010. -Т. 12, № 4-5. -С.385-390.
      14. Schins R.Р.F., Воrm Р. J.А., Van Schooten F.J Neutropihis and respiratory tract DNA damage and mutagenesis: а review // Mutagenesis. -2006. -Vol. 21. -Р. 225-236.
      15. Смирнова О.В., Манчук В. Т., Агилова Ю. Н. Особенности хемилюминесцентной активности нейтрофильных гранулоцитов у больных миеломной болезнью G-формы в зависимости от стадии заболевания // Медицинская иммунология. -2015. -T.17, № 6. -C. 579-584.
      16. Смирнова O.B., Титова Н. М., Елманова Н. Г. Особенности хемилюминисцентной активности нейтрофильных гранулоцитов больных механической желтухой доброкачественного генеза // Российский иммунологический журнал. -2015. T. 2(1) (18). -C. 313-315.
      17. Смирнова О. В., Манчук В. Т., Агилова Ю. Н. Роль неспецифического иммунитета при прогрессировании миеломной болезни // Современные проблемы науки и образования. -2014. -№ 2. -С.515.

    Full text is published :
    Smirnova O. V., Kasparov E. V., Perepechay Ya.I., Versenev A. A., Laletin I. A. THE FEATURES OF NONSPECIFIC IMMUNITY IN THE PROGRESSION OF COLORECTAL CANCER. Experimental and Clinical Gastroenterology Journal. 2018;153(05):73-77
    Read & Download full text

    1. Federal state budgetary institution “national medical and surgical Center. N. And. Pirogov” Ministry of health of the Russian Federation in Moscow (Moscow, Russian Federation)
    2. State budget educational institution of higher professional education “Moscow State medical and dental University. A. I. Evdokimov” (Moscow, Russian Federation)

    Keywords:Yersinia enterocolitica, infliximab, adalimumab, Crohn’s disease, immunosuppressive therapy, mesenchymal stromal bone marrow cells, ulcerative colitis

    Abstract:In patients with ulcerative colitis and Crohn’s disease long-term appointment of biological therapy in combination with GCS/CT increases the frequency of development of yersiniosis infection, which worsens the clinical course of the disease and increases the period of exacerbation. Yersiniosis in inflammatory bowel diseases (IBD), often accompanied by extra-intestinal manifestations of the disease (polyarthritis, erythema nodosa and uveitis). However, the question remains: is yersiniosis a cause of the development of an extra-intestinal manifestation or a sign of reactivation of opportunistic infections against the background of immunosuppressive therapy or an etiological factor of inflammatory bowel diseases? This issue requires further research. According to the literature with inflammatory bowel diseases among the extraintestinal manifestations predominate articular lesions to 42.7% [36]. Although yersiniosis plays a leading role in the pathogenesis of arthritis, clinical and diagnostic studies on yersiniosis were not carried out in IBD. Until now, there are no clear diagnostic and prognostic criteria for the development of adverse outcomes of yersiniosis, in connection with which clinicians do not conduct examinations for the presence of yersiniosis.

      1. Bockemuhl J., Wong J. Yersinia. In Murry P. R., Baron E. J., Jorgansen J. H., Pfaller M. A., Yolken R. H., editors. Manual of clinical microbiology. 8th ed. Wachington (DC): ASMPress; 2003.p.672-83
      2. Дробященко, М. А. Колонизация и размножение YersiniaenterocoliticaО9 в пищевых продуктах, изготовленных в современных технологических условиях / М. А. Дробященко, В. И. Пушкарева, Д. С. Юрьев, В. Ю. Поляков // Эпидемиология и вакцинопрофилактика. - 2010. - № 4 (53). - С. 51-56
      3. Bhaduri, Saumya. Prevalence of pathogenic Yersinia enterocoliticastrains in pigs in the United States / SaumyaBhaduri // Appl. Envirion. Microbiol. - 2005. - № 11 - Р. 7117-7121
      4. Смирнов И. В. Возбудитель иерсиниоза и близкие к нему микроорганизмы // Клин. Микробиолантимикробхимиотер. 2004. Том 6, № 1. С. 10-21.
      5. Иерсиниозы / Н. Д. Ющук, Г. Я. Ценева, Г. Н. Кареткина, Л. Е. Бродов. - М.: Медицина, 2003. - 208 с.
      6. Autenrieth L.B., Firsching R. Penetration of M cells and destruction of Peyer’s patches by Yersinia enterocolitica: an ultrastructural and histological study // J. Med. Microbiol. - 1996. -Vol. 44, № 4. - P.285-294.
      7. Цинзерлинг А. В., Цинзерлинг В. А. Современныеинфекции. Патологическая анатомия и вопросы патогенеза: Рук-во. - СПб: Сотис, 2002. -346 с.
      8. Currie B. Yersinia enterocolitica // Pediatr. Rev. - 1998. - Vol. 19, № 7. - P.250-251.
      9. Бродов Л. Е., Ющук Н. Д., Кареткина Г. Н. и др. Трудности дифференциальной диагностики между рядом инфекционных заболеваний и пищевымитоксикоинфекциями // Клин, медицина. - 1989. - № 7. - С. 131-135
      10. Кареткина Г. Н., Ющук Н. Д., Бродов Л. Е. и др. Клиника и диагностика гастроинтестинальной и абдоминальной формы иерсиниоза // Клин, медицина.-1986.-№ 8. С. 136-139.
      11. Юшук Н. Д., Кузнецов В. Ф., Кареткина Г. Н. и др. Иерсиниоз: Метод, рекомендации. - М.: МЗ РФ, ВНУМЦ,1995. - 20 с.
      12. Кареткина Г. Н., Ющук Н. Д., Бродов Л. Е. и др. Диагностика и лечение генерализованной формы иерсиниоза // Клин, медицина. - 1987. - № 8. -С. 102-105.
      13. Boelaert J. R., van Landuyt H. W., Valcke Y. J. et al. The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients // J. Infect. Dis. - 1987. - Vol.156, № 2. - P. 384-387.
      14. Cauchie P., Vincken W., Peeters O., Charels K. Hemochromatosis and Yersinia enterocolitica septicemia // Dig. Dis. Sci. - 1987. - Vol. 32, № 12. - P. 1438.
      15. Roggencamp A., Ruckdeschel K., Leitritz L. et al. Deletin of amino acids 29 to 81 in adhrsion protein YadA of Yersinia enterocolitica serotype 0:8 results in selective abrogation of adherence to neutrophils // Infect. Immun. - 1996. - Vol. 56.-P. 2506-2514.
      16. Инина Л. И., Иванова М. М., Акимова Р. Т. и др. Клинико-иммунологическая характеристика осложненного и неосложненного иерсиниоза //Вестник АМН CGGP. - 1989. - № 6. - С. 60-65.
      17. Попова О. В. Особенности иммунного ответа при различных формах иерсиниоза: Автореф. дисс… канд. мед.наук. - М., 2006. - 26 с.
      18. Gaston J. S., Lillicrap M. S. Artritis associated with enteric infection //Best Pract. Res. Clin. Rheumatol. - 2003. - Vol. 17. - P. 219-239.
      19. Kvien Т. К., Glennas A., Melby K. et al. Reactive arthritis: incidence, triggering agents and clinical presentation // J. Rheumatol. - 1994. - Vol. 21.-P. 115-122.
      20. Spieper J., Braun J. Reactive arthritis // Curr. Opin.Rheumol. - 1999. -№ 11.-238-243.
      21. Colmegna L, Cuchacovich R., Espinoza L. R. HLA-B27-associated reactive arthritis: Pathogenetic and clinical considerations // Clin. Microbiol.Rev. -2004. - Vol. 17, № 2. - P. 348-369.
      22. Gerard H. C., Branigan P. J., Schumacher H. R., Hudson A. P. Synovial Chlamydia trachomatis in patients with reactive arthritis / Reiters syndrome are viable but show aberrant gene expression // J. Rheumatol. - 1998. - Vol. 25. - P. 734-742.
      23. Granfors K., Merilahti-Palo R., Luukkainen R. et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica 0:3 infection with or without reactive arthritis. // Arthr. and Rheum. - 1998. - Vol. 41. - P. 855.
      24. Toivanen P. From reactive arthritis to rheumatoid arthritis // J. Autoimmun. -2001. - Vol. 16. - P. 369-371.
      25. Meyer-Bahlburg A., Brinkhoff J., Krenn V. et al: Infection of synovial fibroblasts in culture by Yersinia enterocolitica and Samonella enteric serovarenteritidis: ultrastructural investigation with respect to the pathogenesis of reactive arthritis // Infect. And Immun. - 2001. - Vol. 69. - P. 7015-7921
      26. Ющук Н. Д., Кареткина Г. Н. Иерсиниоз как хирургическая проблема // Хирургия. - М., 1999. - № 1 2. - С. 50-52.
      27. Heesemann J., Gaede K., Autenrieth L.B. Experimental Yersinia enterocolitica infection in rodents: a model for human yersiniosis // APMIS. - 1993. -Vol. 101, № 6. - P. 417-429.
      28. Стебунова Т. К. Дифференциальная диагностика и терапия затяжных рецидивирующих форм псевдотуберкулеза у детей: Автореф. дисс. канд. мед.наук. - СПб, 2003. - 24 с.
      29. Учайкин В. Ф. и др. Иерсиниозы у детей / В. Ф. Учайкин, А. В. Гордец, С. Н. Бениова. - М.: ГЭОТАР-Медиа, 2005. - 144 с.
      30. Ющук Н. Д., Шестакова И. В., Шепелева Г. К., Ценева Г. Я., Андреев И. В. К вопросу о формировании иммунопатологии у больных с хроническим течением иерсиниозной инфекции. Сборник докладов. Тезисы V1 Российского съезда инфекционистов. СПб 2003.
      31. Ющук Н. Д., Шестакова И. В., Балмасова И. П. Клинико-прогностические критерии различных форм и вариантов течения иерсиниозной инфекции. Терарх 2009; 81: 11: 44-48.
      32. O’Connor S.M., Taylor Ch.E., Yughes J. M. Emerging infections determinantsof chronic diseases. EmergInfectDis 2006; 12: 7: 1051-1057.
      33. Сафронова А. Н. Микробиологические и экологические особенности штаммов иерсиний, циркулирующих на территории Якутии // Диссер. на соискание ученой степени к. м. н. 2014 г. стр 123.
      34. Шестакова И. В. Иерсиниоз: расширяя традиционные представления о диагностике, лечении и диспансеризации больных / И. В. Шестакова, Н. Д. Ющук // Лечащий врач. - 2010. - № 10. - С. 26.
      35. Ющук Н. Д. Особенности течения и отдаленные исходы генерализованной и вторично-очаговой формы иерсиниозной инфекции больных / Н. Д. Ющук, И. В. Шестакова // Лечащий врач. - 2009. - № 11. - С. 82-86.
      36. Внекишечные проявления неспецифического язвенного колита / Евдокимова Е. Ю. [и др.] //Бюллетень ВСНЦ СО РАМН. - 2005. - № 4 (42). - С. 71.

    Full text is published :
    Read & Download full text

    1. State budgetary institution of high professional education “Moscow State University of Medicine and Dentistry named after A. I. Evdokimov” of the Ministry of Healthcare of the Russian Federation, Department of outpatient therapy (Moscow, Russian Federation)

    Keywords:diverticular disease of the colon conservative therapy, antispasmodics, probiotics, intestinal antiseptics, butyrat

    Abstract:The article presents the results of long-term monitoring of patients diverticular disease of the colon to study the effectiveness of different groups of medicines on the basis of which the proposed rational scheme of treatment according to age of patients, duration of anamnesis of disease and presence of comorbidities. In the period 2003-2016 the study included 396 patients aged 24 to 89 years (mean age 61,4±9.3 years) with instrumental confirmed diverticula of the colon. A big problem in the elderly is polymorbidity and, as a result, forced polypragmasia. In our study of 295 patients over 60 years of age at the time of inclusion in the study had 4.7-5.2 diseases per 1 person. The most common were systemic atherosclerosis, constipation and hyperlipidemia. Constipation was detected in 193 patients (65.4%), hyperlipidemia - in 170 (57.6%). Drugs psillium and lactulose have long been widely known as effective laxatives with prebiotic properties and safe with long-term use. In our study, 120 patients took psyllium and 116-lactulose. For two years, we estimated the number of relapses of NSC (resumption of pain and symptoms of intestinal dyspepsia). It was found that in the psyllium group during the two-year follow-up period the number of recurrences was 20% less than in the lactulose group. Summary. The most effective drug for relief of abdominal pain syndrome in patients with diverticular disease of the colon in all age groups is trimebutin In the treatment of symptomatic diverticular disease of the colon in patients younger than 45 years, it is advisable to prescribe intestinal antiseptics (rifaximin, nifuroxazide) for at least 7 days from the moment of treatment. Patients over 75 years of age need normalization of the stool with the predominant use of laxatives with prebiotic action. When combined with diverticular disease and constipation hyperlipidemia drug of choice is psyllium (mukofalk, vibrolux). At presence at patients of senile age concomitant cardiovascular pathology with the purpose of correction of possible ischemia of the bowel wall at the microscopic level should be provided citoprotected drug of butyric acid.

      1. Kang J.Y., Firwana B., Green A. E. et al. Uncomplicated diverticular disease is not a common cause of colonic symptoms. Aliment.Pham.Ther., 2011, Vol.33(4), P. 487-494
      2. Tursi A, Papa A, Danese S. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Aliment Pharmacol Ther 2015; 42: 664-684
      3. Viniol A, Keunecke C, Biroga T, Stadje R, Dornieden K, Bösner S, Donner-Banzhoff N, Haasenritter J, Becker A Studies of the symptom abdominal pain-a systematic review and meta-analysis. Fam Pract. 2014 Oct;31(5):517-29. doi: 10.1093/fampra/cmu036.
      4. Bevan R, Lee T.J, Nickerson C, Rubin G, Rees C.J; NHS BCSP Evaluation Group. Non-neoplastic findings at colonoscopy after positive faecal occult blood testing: data from the English Bowel Cancer Screening Programme. J Med Screen 2014; 21: 8994.
      5. Kliniko-morfologicheskie varianty divertikulyarnoj bolezni tolstoj kishki. Levchenko S. V., Lazebnik L. B., Potapova V. B., Rogozina V. A. Eksperimental’naya i klinicheskaya gastroehnterologiya 2013 № 3:23–30
      6. Strate L.L, Modi R, Cohen E, Spiegel B.M. Diverticular disease as a chronic illness: evolving epidemiologic and clinical insights. Am J Gastroenterol 2012; 107: 1486-1493
      7. Morris A.M, Regenbogen S.E, Hardiman K.M, Hendren S Sigmoid diverticulitis: a systematic review. JAMA. 2014 Jan 15;311(3):287-97. doi: 10.1001/jama.2013.282025
      8. Spiller R. Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 2012; 30: 64-69
      9. Cuomo R, Barbara G, Andreozzi P, Bassotti G, Casetti T, Grassini M, Ierardi E, Maconi G, Marchi S, Sarnelli G, Savarino V, Usai P, Vozzella L, Annibale B. Symptom patterns can distinguish diverticular disease from irritable bowel syndrome. Eur J Clin Invest 2013; 43: 1147-1155.
      10. Tursi A. Diverticulosis today: unfashionable and still under-researched. Therap Adv Gastroenterol 2016; 9: 213-228
      11. Ford A.C., Talley N. J., Spiegel B. M. et al. Effect of fiber, antispasmodics and peppermint oil in the treatment of irritable bowel syndrome: systematic review and metaanalysis. BMJ, 2008, Now, 337 doi:
      12. Shepberd N.A Diverticular disease in chronic idiopathic inflammatory bowel disease: associations and masquerades Gut 1996; 38:801-2.
      13. Lamps L.W, Knapple W.L. Diverticular disease-associated segmental colitis. Clin Gastroenterol Hepatol 2007;5:27-31]
      14. Levchenko S. V., Gudkova R. B., Potapova V. B., Lazebnik L. B. Reakciya immunokompetentnyh kletok i strukturnye izmeneniya slizistoj obolochki tolstoj kishki u bol’nyh divertikulyarnoj bolezn’yu // EHksperim. i klinich. gastroehnterol. 2009, – № 5. – S. 17–20
      15. Minushkin O. N., Kruchinina M. A. Sindrom izbytochnogo bakterial’nogo rosta u bol’nyh divertikulyarnoj bolezn’yu tolstoj kishki. Kremlevskaya medicina. 2014,1:99–104
      16. Popova E. V. Narushenie sostava kishechnoj mikroflory v mekhanizmah formirovaniya kliniko-morfologicheskih proyavlenij u bol’nyh divertikulyarnoj bolezn’yu tolstoj kishki. Diss. k. m.n., 2012,121 str
      17. Komissarenko I. A., Levchenko S. V., Gudkova R. B., Sil’vestrova S. Yu. Effekty dlitel’nogo primeneniya psilliuma pri lechenii bol’nyh s divertikulyarnoj bolezn’yu tolstoj kishki. // KPGG, 2014:3: 29–36
      18. Strate L.L., Liu Y. L., Aldoori W. H. et al. Obesity increases the risks of diverticulitis and diverticular bleeding, Gastroenterol., 2009, 136(1), P. 115-22
      19. Kopylov U, Ben-Horin S, Lahat A, Segev S. Obesity, metabolic syndrome and the risk of development of colonic diverticulosis, Digestion 2012;86(3):201-5
      20. Levchenko S. V., Lazebnik L. B., Potapova V. B., Rogozina V. A. Kliniko-morfologicheskie varianty divertikulyarnoj bolezni tolstoj kishki. Eksperimental’naya i klinicheskaya gastroehnterologiya 2013 № 3:23–20
      21. Krokowicz L., Stojcev Z, Kaczmarek B.F, Kociemba W, Kaczmarek E, Walkowiak J, Krokowicz P, Drews M, Banasiewicz T. Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis - a prospective randomized study. Int J Colorectal Dis. 2014 Mar;29(3):387-93. doi: 10.1007/s00384-013-1807-5

    Full text is published :
    Boytsov S. A., Lazebnik L. B., Levchenko S. V., Komissarenko I. A. RATIONAL PHARMACOTHERAPY OF THE SYMPTOMATIC UNCOMPLICATED COLON DIVERTICULAR DISEASE. Experimental and Clinical Gastroenterology Journal. 2018;153(05):86-92
    Read & Download full text